Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

被引：18

作者：

Shah, Nirav N. ^{[1
]}

Krishnan, Amrita Y. ^{[2
]}

Shah, Nina D. ^{[3
]}

Burke, John M. ^{[4
]}

Melear, Jason M. ^{[5
]}

Spira, Alexander I. ^{[6
]}

Popplewell, Leslie L. ^{[2
]}

Andreadis, Charalambos B.

Chhabra, Saurabh

Sharman, Jeff P.

Kaufman, Jonathan L.

Cohen, Jonathon B.

Niesvizky, Ruben ^{[7
]}

Martin, Thomas G., III ^{[3
]}

Dilea, Clifford ^{[8
]}

Kuriakose, Jason ^{[9
]}

Matheny, Shannon L. ^{[9
]}

Leonard, John P. ^{[10
]}

Molina, Arturo ^{[9
]}

机构：

[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[2] City Hope Med Ctr, Duarte, CA USA

[3] Univ Calif San Francisco, San Francisco, CA 94143 USA

[4] Rocky Mt Canc Ctr, Aurora, CO USA

[5] Texas Oncol, Austin, TX USA

[6] Virginia Canc Specialists Res Inst, Fairfax, VA USA

[7] Weill Cornell Med Coll, Div Hematol & Med Oncol, New York, NY USA

[8] Aclairo Pharmaceut Dev Grp Inc, Vienna, VA USA

[9] Sutro Biopharma, San Francisco, CA USA

[10] Weill Cornell Med Coll, Pelham Manor, NY USA

来源：

关键词：

D O I：

10.1182/blood-2019-122754

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5329

引用

页数：5